Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 4Lymphoma 3Lymphoma, Follicular 2Vomiting 1Pyloric Stenosis, Hypertrophic 1Nausea 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1HIV Infections 1

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × R-CHOP protocol × Clear all
NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

University of Chicago

Phase 2 Active not recruiting
51 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡